<DOC>
	<DOC>NCT03099083</DOC>
	<brief_summary>The objective of this non-interventional, observational study is to assess the effect of adalimumab on health-related quality of life in participants with Psoriasis in Korea.</brief_summary>
	<brief_title>Real-World Outcome of Psoriasis Subjects in Korea on Adalimumab</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Adalimumab</mesh_term>
	<criteria>Participant has a diagnosis of Psoriasis by investigator. Participant (local definition according to adalimumab label) who is in compliance with eligibility for adalimumab based on the local label. Participant must be able and willing to provide written informed consent and comply with the requirements of this study protocol. Participants who are pregnant or breast feeding at enrolment or wish to become pregnant in the next 24 weeks. Participation in any Psoriasisrelated clinical trial at the time of enrolment, at baseline or at any point during the study period. Participants, who in the investigator's view, may not be able to accurately report their questionnaires</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Adalimumab</keyword>
	<keyword>Psoriasis</keyword>
	<keyword>Humira</keyword>
	<keyword>Korea</keyword>
</DOC>